Abstract 103P
Background
Though definitive chemoradiotherapy(dCRT) is the standard of care for unresectable esophageal squamous cell carcinoma (ESCC), there are still 30-40% of patients with distant metastasis. Immunotherapy (IO) has been proven to be effective for patients with advanced metastasis ESCC. It is of great clinical value to discover the combination mode of CRT and IO in the real world, and to evaluate its efficacy and safety for optimizing the treatment strategy in the subsequent clinical practice.
Methods
This is a multicenter, single-arm, prospective real-world study. We planned to enroll patients with newly diagnosed locally advanced ESCC who were unresectable or refused surgery. Patients who had not received previous anti-tumor therapy (surgery, radiotherapy, chemotherapy, IO). Patients were expected to receive at least 2 cycles of tislelizumab. The primary endpoint was 2-year survival. Secondary endpoints were ORR, PFS, TRAE, and irAE.
Results
From March 2022 to November 2023, a total of 58 patients with locally advanced unresectable ESCC were enrolled in 15 centers. The average age was 61 years, and stage II, III, and IVa accounted for 22%, 38%, and 40%, respectively. In the real world, there were three treatment modes of IO combined with CRT, including concurrent CRT combined with IO, IO sequential consolidation therapy after CRT, and IO combined with chemotherapy induction followed by CRT, with the proportions of 48%, 21%, and 31%, respectively. A total of 53 patients were evaluated for efficacy, with an ORR of 79% and a DCR of 100%. As of the data cutoff date, a total of 8 patients had progressed and 10 patients had died. The 1-year PFS rate was 75.8%, and the 1-year OS rate was 81.2%. Most of the adverse events were grade 1-2, and grade 3 TRAE occurred in 4 patients, including 1 case of radiation pneumonitis, 1 case of immune pneumonitis, 1 case of esophagitis and 1 case of platelet inhibition. One patient died of esophageal fistula. Three patients withdrew from treatment due to adverse reactions.
Conclusions
For patients with unresectable locally advanced ESCC, dCRT combined with immunotherapy has good efficacy and controllable safety in the real world.
Clinical trial identification
ChiCTR2200059190.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract